Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CND004
MIFTS: 57

Candidiasis

Categories: Blood diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Candidiasis

About this section

MalaCards integrated aliases for Candidiasis:

Name: Candidiasis 12 73 54 44 15 70 32
Systemic Candidiasis 12 20 70
Invasive Candidiasis 20 3 70
Disseminated Candidiasis 12 54
Systemic Candida Infections 20
Candidiasis, Invasive 17

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases Genetic diseases
Anatomical: Blood diseases Gastrointestinal diseases Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1508
ICD9CM 34 112
MeSH 44 D002177
NCIt 50 C26711
SNOMED-CT 67 154403005
ICD10 32 B37 B37.9
UMLS 70 C0006840 C0153252 C1609535
Sources

Summaries for Candidiasis

About this section
CDC : 3 Invasive candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Unlike Candida infections in the mouth and throat (also called "thrush") or vaginal "yeast infections," which are localized to one part of the body, invasive candidiasis is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body.1 Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on the skin without causing any problems.2 However, in certain patients who are at risk, Candida can enter the bloodstream or internal organs and cause an infection. A Candida bloodstream infection, also called candidemia, is the most common form of invasive candidiasis.1 In the United States, candidemia is one of the most common causes of bloodstream infections in hospitalized patients,3–4 and it often results in long hospital stays and death. It is also responsible for high medical costs.5 Antifungal medication can treat invasive candidiasis. Certain patients such as those with cancer or bone marrow or organ transplants might receive antifungal medication to prevent invasive candidiasis.6

MalaCards based summary : Candidiasis, also known as systemic candidiasis, is related to candidiasis, familial, 2 and vulvovaginal candidiasis. An important gene associated with Candidiasis is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Fluticasone and Voriconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and bone marrow, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An opportunistic mycosis that involves fungal infection of the mouth, throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, heart and brain by Candida species, of which Candida albicans is the most common. Systemic Candida infections are usually confined to severely immunocompromised persons.

GARD : 20 Systemic candidiasis includes a spectrum of yeast infections caused by different species (types) of Candida. It is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body. Although there are over 200 species of Candida, five different species of Candida cause 90% of systemic candidiasis. The most common form of this invasive yeast infection is when Candida enters the bloodstream (candidemia). Signs of candidemia include fever and chills that do not improve with antibiotics. Symptoms of other types of systemic candidiasis depend on the organ or system which is infected. Systemic candidiasis is the most common fungal infection among hospitalized people in high-income countries, including the United States. Diagnosis can be difficult, especially when the Candida is not found in the bloodstream. Treatment usually includes consists of oral or intravenous (IV) antifungal medications.

Wikipedia : 73 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Sources

Related Diseases for Candidiasis

About this section

Diseases in the Candidiasis family:

Candidiasis, Familial, 1 Candidiasis, Familial, 2
Candidiasis, Familial, 3 Candidiasis, Familial, 4
Candidiasis, Familial, 6 Candidiasis, Familial, 8
Candidiasis, Familial, 9

Diseases related to Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 743)
# Related Disease Score Top Affiliating Genes
1 candidiasis, familial, 2 33.0 TRAF3IP2-AS1 TRAF3IP2 CLEC7A CARD9
2 vulvovaginal candidiasis 33.0 SKAP2 DEFB4A CLEC7A CARD9
3 esophageal candidiasis 33.0 IL17A CLEC7A CARD9 AIRE
4 candidiasis, familial, 8 32.9 TRAF3IP2-AS1 TRAF3IP2
5 neonatal candidiasis 32.9 CLEC7A CARD9
6 candidal paronychia 32.6 TRAF3IP2 IL17RC
7 cutaneous candidiasis 32.4 IL17RC IL17RA IL17F IL17A CLEC7A CARD9
8 autoimmune polyendocrine syndrome type 1 31.8 IL17RA IL17F IL17A CLEC7A CARD9 AIRE
9 candida glabrata 31.8 SKAP2 HTN3 APCS
10 chronic mucocutaneous candidiasis 31.8 TRAF3IP2-AS1 TRAF3IP2 STAT1 IL17RC IL17RA IL17F
11 polyendocrinopathy 31.8 STAT1 AIRE
12 oral candidiasis 31.6 STAT1 SKAP2 SH2D1A IL17RA IL17A HTN3
13 vaginitis 31.6 SH2D1A IL10 DEFB4A
14 cryptococcosis 31.1 IL17A IL10 CLEC7A CARD9
15 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 IL17A IL10 AIRE
16 autoimmune polyendocrine syndrome 30.9 IL17A IL10 AIRE
17 denture stomatitis 30.8 SKAP2 DEFB4A
18 lichen planus 30.8 IL17A IL10 DEFB4A
19 dermatophytosis 30.7 STAT1 IL17A DEFB4A CLEC7A CARD9
20 dermatitis 30.7 STAT1 IL17A IL10 DEFB4A
21 dermatomycosis 30.7 CLEC7A CHIT1
22 autoimmune hepatitis 30.6 IL17A IL10 AIRE
23 alopecia areata 30.5 IL17A IL10 AIRE
24 thyroiditis 30.5 IL17A IL10 AIRE
25 fungal infectious disease 30.5 STAT1 SKAP2 IL17RC IL17RA IL17F IL17A
26 mycobacterium tuberculosis 1 30.5 STAT1 IL17A IL10 CLEC7A
27 tinea pedis 30.5 DEFB4A CLEC7A CARD9
28 sporotrichosis 30.4 IL10 CLEC7A CARD9
29 disease by infectious agent 30.4 IL17A IL10 HSP90AA1 DEFB4A
30 hyper ige syndrome 30.4 IL17RA IL17F IL17A IL10 CARD9
31 blastomycosis 30.4 IL17A CLEC7A CARD9
32 coccidioidomycosis 30.3 STAT1 IL17A CLEC7A CARD9
33 trichosporonosis 30.3 CLEC7A CARD9
34 immune deficiency disease 30.3 STAT1 SH2D1A IL17A IL10 APCS AIRE
35 psoriasis 30.2 TRAF3IP2 IL17F IL17A IL10 DEFB4A
36 mycetoma 30.2 IL17A IL10 CHIT1
37 crohn's disease 30.2 IL17F IL17A IL10 DEFB4A CARD9
38 tinea cruris 30.2 DEFB4A CARD9
39 periodontitis 30.1 IL17A IL10 DEFB4A
40 salmonellosis 30.1 STAT1 IL17A IL10 DEFB4A
41 psoriasis 13 30.0 TRAF3IP2-AS1 TRAF3IP2
42 neurosyphilis 30.0 IL17A IL10
43 tinea corporis 30.0 DEFB4A CLEC7A CARD9
44 colitis 29.9 IL17RA IL17A IL10 DEFB4A
45 opportunistic mycosis 29.9 STAT1 SKAP2 IL17RC IL17RA IL17F IL17A
46 proteasome-associated autoinflammatory syndrome 1 29.9 STAT1 IL17A IL10
47 bacterial pneumonia 29.9 IL17A IL10 DEFB4A
48 psoriatic arthritis 29.9 TRAF3IP2 IL17RA IL17A IL10
49 vaginal disease 29.8 SKAP2 IL17A IL10 DEFB4A CLEC7A CARD9
50 contact dermatitis 29.8 IL17F IL17A IL10 DEFB4A

Comorbidity relations with Candidiasis via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Intestinal Obstruction
Paralytic Ileus Protein-Energy Malnutrition
Respiratory Failure

Graphical network of the top 20 diseases related to Candidiasis:



Diseases related to Candidiasis
Sources

Symptoms & Phenotypes for Candidiasis

About this section

MGI Mouse Phenotypes related to Candidiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 AIRE APCS CARD9 CLEC7A IL10 IL17A
2 immune system MP:0005387 9.83 AIRE APCS CARD9 CHIT1 CLEC7A HSP90AA1
3 digestive/alimentary MP:0005381 9.8 AIRE CLEC7A IL10 IL17A IL17F STAT1
4 respiratory system MP:0005388 9.23 AIRE CLEC7A IL10 IL17A IL17F IL17RA
Sources

Drugs & Therapeutics for Candidiasis

About this section

Drugs for Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
2
Voriconazole Approved Phase 4 137234-62-9 71616
3
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
6
Terconazole Approved Phase 4 67915-31-5 441383
7
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
8
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
9
Dequalinium Approved, Investigational Phase 4 6707-58-0
10
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
11
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
12
Nevirapine Approved Phase 4 129618-40-2 4463
13
Zidovudine Approved Phase 4 30516-87-1 35370
14
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
17
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
18
Salmeterol xinafoate Phase 4 94749-08-3 56801
19 Adrenergic Agonists Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Adrenergic beta-Agonists Phase 4
22 Fluticasone-Salmeterol Drug Combination Phase 4
23 Neurotransmitter Agents Phase 4
24 Adrenergic Agents Phase 4
25 Sympathomimetics Phase 4
26 Anti-Allergic Agents Phase 4
27 Bronchodilator Agents Phase 4
28 Liver Extracts Phase 4
29 Antiparasitic Agents Phase 4
30 Liposomal amphotericin B Phase 4
31 Antiprotozoal Agents Phase 4
32 Anti-Bacterial Agents Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
35 Hydrocortisone 17-butyrate 21-propionate Phase 4
36 Hydrocortisone hemisuccinate Phase 4
37 Anti-Inflammatory Agents Phase 4
38 Clindamycin palmitate Phase 4
39 Clindamycin phosphate Phase 4
40 Ionophores Phase 4
41 Anti-Retroviral Agents Phase 4
42 Cytochrome P-450 CYP3A Inhibitors Phase 4
43 Anti-Infective Agents, Local Phase 4
44
tannic acid Approved Phase 3 1401-55-4
45
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
46
Isavuconazole Approved, Investigational Phase 3 241479-67-4
47
Metronidazole Approved Phase 3 443-48-1 4173
48
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
49
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
50
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Multicenter Study to Compare Two Diagnostic Tests (1,3-β-D-glucan vs Blood Culture) in Critically Ill Patients With Suspected Invasive CAndidiasis Hospitalized in Internal Medicine Wards and Who Are Currently Timely Treated With Echinocandin (Micafungin) Unknown status NCT03906916 Phase 4 Micafungin
2 A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
3 Diagnosis of Pulmonary Candidiasis Unknown status NCT00537888 Phase 4 fluconazole
4 Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
5 CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients Completed NCT00670657 Phase 4 AmBisome
6 A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
7 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
8 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
9 Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis Completed NCT01994096 Phase 4 Caspofungin
10 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients Completed NCT01734525 Phase 4 Anidulafungin
11 Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
12 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
13 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
14 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
15 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
16 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
17 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
18 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
19 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Completed NCT03723525 Phase 4
20 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
21 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
22 Oral Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
23 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
24 Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk Completed NCT00001107 Phase 4 Fluconazole;AmBisome
25 The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients Completed NCT01495039 Phase 4 Nystatin
26 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
27 Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA) Recruiting NCT04122560 Phase 4 Fluconazole 200mg tab;Fluconazole 2 MG/ML
28 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
29 A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis. Recruiting NCT04699240 Phase 4 clotrimazole vaginal tablets;Clotrimazole vaginal tablets+ Lactobacillus
30 A Randomized Controlled Trial to Compare the Efficacy of a Medical Grade Honey Formulation (L-Mesitran®) and Fluconazol (Diflucan®) for the Treatment of Recurrent Vulvovaginal Candidiasis Not yet recruiting NCT04626258 Phase 4 Fluconazole
31 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment) Terminated NCT01982071 Phase 4 Micafungin
32 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
33 A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
34 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Unknown status NCT03473418 Phase 3 Ketoconazole;Terconazole
35 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
36 "A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ". Unknown status NCT02635438 Phase 3 Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
37 Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates) Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
38 A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA Completed NCT00761267 Phase 3 Anidulafungin;Fluconazole
39 A Single Center, Open, Parallel, Comparative, Randomized Study of Micafungin (FK463) vs Fluconazole (Diflucan) in the Treatment of Invasive Candidiasis and Candidaemia (Protocol No: MCFGCAN-0301F-TW) Completed NCT00189709 Phase 3 Micafungin;fluconazole
40 Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial Completed NCT01773876 Phase 3 Micafungin;PLACEBO
41 A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
42 A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults Completed NCT00635648 Phase 3 caspofungin acetate
43 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations Completed NCT00689338 Phase 3 Anidulafungin;Fluconazole;Voriconazole
44 A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults Completed NCT00250432 Phase 3 caspofungin acetate
45 A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications. Completed NCT00056368 Phase 3 Anidulafungin;Fluconazole
46 A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia Completed NCT00106288 Phase 3 Micafungin;Liposomal Amphotericin B
47 A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients With Invasive Candidiasis or Candidemia Completed NCT00105144 Phase 3 Micafungin;Caspofungin
48 A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections Completed NCT00413218 Phase 3 Isavuconazole;Caspofungin;Voriconazole
49 A Phase III, Double Blind, Randomized, Multi-Center Study of the Safety and Efficacy of Anidulafungin VS. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications Completed NCT00058682 Phase 3 Anidulafungin
50 A Randomized Double-Masked Trial of Caspofungin Versus Placebo as Prophylaxis of Invasive Candidiasis in High-Risk Adults in the Critical Care Setting Completed NCT00099775 Phase 3 Caspofungin

Search NIH Clinical Center for Candidiasis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Flucytosine

Cochrane evidence based reviews: candidiasis

Sources

Genetic Tests for Candidiasis

About this section
Sources

Anatomical Context for Candidiasis

About this section

MalaCards organs/tissues related to Candidiasis:

40
Skin, Kidney, Bone Marrow, Neutrophil, Bone, Tongue, Myeloid
Sources

Publications for Candidiasis

About this section

Articles related to Candidiasis:

(show top 50) (show all 15577)
# Title Authors PMID Year
1
Candidemia and invasive candidiasis in adults: A narrative review. 20 61
27394927 2016
2
T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. 61 20
26371384 2016
3
[HBD-1 and hBD-2 are expressed in cervico-vaginal lavage in female genital tract due to microbial infections]. 61 54
20476598 2010
4
Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. 54 61
19196253 2009
5
Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED. 61 54
19037923 2008
6
Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. 61 54
18606876 2008
7
Efungumab and caspofungin: pre-clinical data supporting synergy. 54 61
18299636 2008
8
[Preliminary evaluation of a vaginal cream containing lactoferrin in the treatment of vulvovaginal candidosis]. 54 61
18487962 2008
9
The autoimmune regulator PHD finger binds to non-methylated histone H3K4 to activate gene expression. 54 61
18292755 2008
10
Recurrent herpes simplex virus infection in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy associated with L29P and IVS9-1G>C compound heterozygous autoimmune regulator gene mutations. 61 54
17547716 2007
11
Production of hybrid phage displaying secreted aspartyl proteinase epitope of Candida albicans and its application for the diagnosis of disseminated candidiasis. 54 61
17472610 2007
12
Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. 54 61
16940535 2006
13
Ets transcription factors regulate AIRE gene promoter. 61 54
16890195 2006
14
Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. 54 61
16784312 2006
15
Disruption of immunological tolerance: role of AIRE gene in autoimmunity. 54 61
16431348 2006
16
Immunodeficiencies with autoimmune consequences. 54 61
16682278 2006
17
The monopartite nuclear localization signal of autoimmune regulator mediates its nuclear import and interaction with multiple importin alpha molecules. 61 54
16403019 2006
18
Functional analysis of SAND mutations in AIRE supports dominant inheritance of the G228W mutation. 61 54
16114041 2005
19
Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. 61 54
15963364 2005
20
AIRE and immunological tolerance: insights from the study of autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy. 61 54
15640689 2004
21
Autoimmune regulator induced changes in the gene expression profile of human monocyte-dendritic cell-lineage. 54 61
15482854 2004
22
Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. 54 61
15378761 2004
23
Potential usefulness of bovine lactoferrrin for adjunctive immunotherapy for mucosal Candida infections. 54 61
15222472 2004
24
Recombinant antibodies: a natural partner in combinatorial antifungal therapy. 61 54
15040939 2004
25
Efficacy of human salivary mucin MUC7-derived peptide and histatin 5 in a murine model of candidiasis. 61 54
14659657 2003
26
Life-threatening autoimmunity with diabetes: management with an insulin pump. 54 61
14655274 2003
27
Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. 54 61
12870130 2003
28
Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. 54 61
12821470 2003
29
The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. 61 54
12761103 2003
30
Characterization of regulatory elements and methylation pattern of the autoimmune regulator (AIRE) promoter. 54 61
12651856 2003
31
A novel AIRE mutation in an APECED patient with candidiasis, adrenal failure, hepatitis, diabetes mellitus and osteosclerosis. 54 61
12784192 2003
32
New sensitive method for the measurement of lysozyme and lactoferrin to explore mucosal innate immunity. Part II: time-resolved immunofluorometric assay used in HIV patients with oral candidiasis. 61 54
12666997 2003
33
Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. 61 54
12542742 2002
34
A novel missense mutation of AIRE gene in a patient with autoimmune polyendocrinopathy, candidiasis and ectodermal dystrophy (APECED), accompanied with progressive muscular atrophy: case report and review of the literature in Japan. 54 61
12625412 2002
35
Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. 61 54
12439202 2002
36
The secreted aspartic proteinases as a new target in the therapy of candidiasis. 54 61
12182226 2002
37
Secreted aspartic proteases as virulence factors of Candida species. 54 61
12437091 2002
38
Evidence for differential expression of candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1-transgenic mice. 54 61
11930319 2002
39
Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. 54 61
11936455 2002
40
Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. 61 54
11807692 2002
41
Aspartyl proteinases of Candida albicans and their role in pathogenicity. 61 54
11556759 2001
42
HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. 54 61
11476984 2001
43
Antifungal antibodies: a new approach to the treatment of systemic candidiasis. 54 61
11566001 2001
44
Subcellular location and expression pattern of autoimmune regulator (Aire), the mouse orthologue for human gene defective in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED). 61 54
11156688 2001
45
Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. 61 54
10733678 2000
46
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. 54 61
10395861 1999
47
Clinical strains of Candida albicans express the surface antigen glyceraldehyde 3-phosphate dehydrogenase in vitro and in infected tissues. 61 54
10219595 1999
48
Chromosomal localization and complete genomic sequence of the murine autoimmune regulator gene (Aire). 54 61
10593569 1999
49
A common and recurrent 13-bp deletion in the autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy type 1. 54 61
9837820 1998
50
Chronic vaginal candidiasis responsive to biotin therapy in a carrier of biotinidase deficiency. 54 61
9764646 1998
Sources

Variations for Candidiasis

About this section
Sources

Expression for Candidiasis

About this section
Search GEO for disease gene expression data for Candidiasis.
Sources

Pathways for Candidiasis

About this section

Pathways related to Candidiasis according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.66 STAT1 SH2D1A IL17RC IL17RA IL17F IL17A
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.16 STAT1 IL17RC IL17RA IL17F IL17A IL10
3
Th17 cell differentiation 36
Show member pathways
 12.34 STAT1 IL17F IL17A IL10 HSP90AA1
4
NF-kappaB Signaling 4
12.28 STAT1 SH2D1A IL17A IL10 CARD9
5
NOD-like receptor signaling pathway 36
12.04 STAT1 HSP90AA1 DEFB4A CARD9
6
Tuberculosis 36
12.01 STAT1 IL10 CLEC7A CARD9
7
C-type lectin receptor signaling pathway 36
Show member pathways
 11.97 STAT1 IL10 CLEC7A CARD9
8
Interleukin-4 and 13 signaling 65
11.61 STAT1 IL17F IL17A IL10 HSP90AA1
9
Th17 Differentiation Pathway 64
Show member pathways
 11.58 STAT1 IL17RA IL17F IL17A
10
Th1 Differentiation Pathway 64
Show member pathways
 11.55 STAT1 IL17A IL10
11
IL-17 Family Signaling Pathways 64
Show member pathways
 11.5 TRAF3IP2 IL17RC IL17RA IL17F IL17A HSP90AA1
12
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.32 TRAF3IP2 IL17RC IL17RA IL17F IL17A
Sources

GO Terms for Candidiasis

About this section

Cellular components related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 IL17RA IL17F IL17A IL10 HTN3 HSP90AA1

Biological processes related to Candidiasis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.03 SH2D1A IL17RA IL17F IL17A CLEC7A CARD9
2 immune response GO:0006955 9.97 IL17A IL10 DEFB4A CHIT1 AIRE
3 innate immune response GO:0045087 9.91 SH2D1A IL17RA IL17F IL17A CLEC7A CARD9
4 inflammatory response GO:0006954 9.88 TRAF3IP2 IL17RC IL17RA IL17F IL17A CLEC7A
5 cytokine-mediated signaling pathway GO:0019221 9.8 STAT1 IL17RC IL17F IL17A IL10 HSP90AA1
6 defense response to Gram-positive bacterium GO:0050830 9.78 IL17F IL17A DEFB4A CARD9
7 positive regulation of tumor necrosis factor production GO:0032760 9.76 IL17A CLEC7A CARD9
8 defense response to Gram-negative bacterium GO:0050829 9.75 IL17F IL17A DEFB4A
9 humoral immune response GO:0006959 9.72 TRAF3IP2 SH2D1A AIRE
10 positive regulation of defense response to virus by host GO:0002230 9.69 TRAF3IP2 STAT1 HSP90AA1
11 defense response to fungus GO:0050832 9.67 IL17RC IL17A HTN3
12 regulation of interleukin-6 production GO:0032675 9.59 IL17F CARD9
13 positive regulation of interleukin-23 production GO:0032747 9.54 IL17RA IL17A
14 fibroblast activation GO:0072537 9.52 IL17RA IL17A
15 regulation of interleukin-2 production GO:0032663 9.46 IL17F CARD9
16 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.46 IL17RC IL17F IL17A CLEC7A
17 positive regulation of antimicrobial peptide production GO:0002225 9.43 IL17F IL17A
18 positive regulation of chemokine (C-X-C motif) ligand 1 production GO:2000340 9.43 IL17RA IL17F IL17A
19 positive regulation of interleukin-6 production GO:0032755 9.43 IL17RC IL17RA IL17F IL17A CLEC7A CARD9
20 interleukin-17-mediated signaling pathway GO:0097400 9.02 TRAF3IP2 IL17RC IL17RA IL17F IL17A

Molecular functions related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-17 receptor activity GO:0030368 8.62 IL17RC IL17RA
Sources

Sources for Candidiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....